A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients.

@article{Viens2006API,
  title={A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients.},
  author={Patrice Viens and Thierry Petit and Alejandro Yovine and Philippe Bougnoux and Ga{\"e}l Deplanque and P. Cottu and R{\'e}my Delva and Jean-pierre Lotz and Simon J. P. Van Belle and J. M. Extra and Esteban Cvitkovic},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2006},
  volume={17 3},
  pages={429-36}
}
PURPOSE A multicentric, phase II study to evaluate the efficacy and safety of the combination paclitaxel and oxaliplatin in patients with platinum-sensitive recurrent ovarian cancer. PATIENTS AND METHODS Patients received 175 mg/m(2) paclitaxel (over 3 h) followed by 130 mg/m(2) oxaliplatin (over 2 h) every 21 days for up to nine cycles without hydration or primary granulocyte colony-stimulating factor prophylaxis. Patients had to have an Eastern Cooperative Oncology Group performance status… CONTINUE READING